{"disease":{"id":"mismatch-repair-proficient-pmmr-rectal-cancer","name":"mismatch repair proficient pmmr rectal cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07175636","title":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06522919","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}